Rheumotologitsts’ view on the use of hydroxychloroquine to treat COVID-19
The current pandemic coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls urgently for effective therapies. Anti-malarial medicine chloroquine (CQ) and particularly its chemical analogue hydroxychloroquine (HCQ) have been recommended as...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-01-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2020.1760145 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849731616777175040 |
|---|---|
| author | Xiaoxuan Sun Yicheng Ni Miaojia Zhang |
| author_facet | Xiaoxuan Sun Yicheng Ni Miaojia Zhang |
| author_sort | Xiaoxuan Sun |
| collection | DOAJ |
| description | The current pandemic coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls urgently for effective therapies. Anti-malarial medicine chloroquine (CQ) and particularly its chemical analogue hydroxychloroquine (HCQ) have been recommended as promising candidate therapeutics that are now under either compassionate off-label use or clinical trials for the treatment of COVID-19 patients. However, there are public concerns and disputes about both the safety and efficacy of CQ and HCQ for this new application. Given the fact that for decades HCQ has been approved as an immunomodulatory drug for the long term treatment of chronic rheumatic diseases, as experienced rheumatologists, we would like to share our thoughts in this regard and trigger a brainstorm among clinical care providers for exchanging their diverse opinions on this urgent topic. |
| format | Article |
| id | doaj-art-dae8abe22d9d4ea2b9f9ff10f76ad984 |
| institution | DOAJ |
| issn | 2222-1751 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-dae8abe22d9d4ea2b9f9ff10f76ad9842025-08-20T03:08:29ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512020-01-019183083210.1080/22221751.2020.1760145Rheumotologitsts’ view on the use of hydroxychloroquine to treat COVID-19Xiaoxuan Sun0Yicheng Ni1Miaojia Zhang2Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of ChinaDepartment of Imaging & Pathology, Faculty of Medicine, KU Leuven, BelgiumDepartment of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, People’s Republic of ChinaThe current pandemic coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls urgently for effective therapies. Anti-malarial medicine chloroquine (CQ) and particularly its chemical analogue hydroxychloroquine (HCQ) have been recommended as promising candidate therapeutics that are now under either compassionate off-label use or clinical trials for the treatment of COVID-19 patients. However, there are public concerns and disputes about both the safety and efficacy of CQ and HCQ for this new application. Given the fact that for decades HCQ has been approved as an immunomodulatory drug for the long term treatment of chronic rheumatic diseases, as experienced rheumatologists, we would like to share our thoughts in this regard and trigger a brainstorm among clinical care providers for exchanging their diverse opinions on this urgent topic.https://www.tandfonline.com/doi/10.1080/22221751.2020.1760145COVID-19SARS-CoV-2therapyhydroxychloroquine (HCQ)Chloroquine (CQ) |
| spellingShingle | Xiaoxuan Sun Yicheng Ni Miaojia Zhang Rheumotologitsts’ view on the use of hydroxychloroquine to treat COVID-19 Emerging Microbes and Infections COVID-19 SARS-CoV-2 therapy hydroxychloroquine (HCQ) Chloroquine (CQ) |
| title | Rheumotologitsts’ view on the use of hydroxychloroquine to treat COVID-19 |
| title_full | Rheumotologitsts’ view on the use of hydroxychloroquine to treat COVID-19 |
| title_fullStr | Rheumotologitsts’ view on the use of hydroxychloroquine to treat COVID-19 |
| title_full_unstemmed | Rheumotologitsts’ view on the use of hydroxychloroquine to treat COVID-19 |
| title_short | Rheumotologitsts’ view on the use of hydroxychloroquine to treat COVID-19 |
| title_sort | rheumotologitsts view on the use of hydroxychloroquine to treat covid 19 |
| topic | COVID-19 SARS-CoV-2 therapy hydroxychloroquine (HCQ) Chloroquine (CQ) |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2020.1760145 |
| work_keys_str_mv | AT xiaoxuansun rheumotologitstsviewontheuseofhydroxychloroquinetotreatcovid19 AT yichengni rheumotologitstsviewontheuseofhydroxychloroquinetotreatcovid19 AT miaojiazhang rheumotologitstsviewontheuseofhydroxychloroquinetotreatcovid19 |